Value Investor
Start free

Annovis Bio

ANVS on NYSE. Market value $51m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

What to watch out for

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 61 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $4m of shares on the open market.

  • Hoffman Michael B
    Director
    Bought
    Date
    20 May 2026
    Shares
    76,344
    Price
    $1.87
    Value
    $142,784
  • Hoffman Michael B
    Director
    Bought
    Date
    2 April 2026
    Shares
    713,800
    Price
    $2.10
    Value
    $1m
  • Hoffman Michael B
    Director
    Bought
    Date
    8 December 2025
    Shares
    45,000
    Price
    $4.31
    Value
    $193,800
  • Hoffman Michael B
    Director
    Bought
    Date
    24 November 2025
    Shares
    39,200
    Price
    $4.08
    Value
    $159,886
  • Hoffman Michael B
    Director
    Bought
    Date
    21 November 2025
    Shares
    20,000
    Price
    $3.50
    Value
    $69,900
  • Hoffman Michael B
    Director
    Bought
    Date
    14 November 2025
    Shares
    15,000
    Price
    $2.11
    Value
    $31,650
  • Maccecchini Maria-Luisa
    President & CEO, Director
    Bought
    Date
    28 October 2025
    Shares
    97,561
    Price
    $2.05
    Value
    $200,000
  • Hoffman Michael B
    Director
    Bought
    Date
    28 October 2025
    Shares
    975,610
    Price
    $2.05
    Value
    $2m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Annovis Bio’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 13 Mar 2026, plus the 10-Q filed 14 Aug 2026 and 8 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these financial statements are issued.”
    Show the full paragraph
    We have never been profitable and have incurred net losses since inception. Our accumulated deficit at June 30, 2026 was $196.1 million. We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements until the fourth quarter of 2026. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of, or cease, our operations. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these financial statements are issued.

    From the 10-Q filed 14 August 2026, Part I, Item 2. Management's Discussion and Analysis. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.